Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christos Chouaid

Showing results (181-190 of 193) with videos related to

Pageof 20
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 21, 2023
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018Olivier Bylicki, Pascale Tomasini, Gervais Radj, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2015
Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II StudyBenjamin Besse, Sylvestre Le Moulec, Julien Mazières, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 18, 2012
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2)Jacques Cadranel, Audrey Mauguen, Michele Faller, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R StudyNicolas Girard, Jair Bar, Pilar Garrido, et al.
Current Oncology (Toronto, Ont.)|March 27, 2026
Real-World Treatment Patterns and Survival in Patients with <i>ROS1</i>-Positive Advanced Non-Small Cell Lung Cancer in Canada and EuropeWinson Y Cheung, Adam Lee, Helena Bote de Cabo, et al.
Advances in Therapy|January 18, 2023
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion MutationsChristos Chouaid, Lise Bosquet, Nicolas Girard, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2011
Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1)Michèle Beau-Faller, Armelle Degeorges, Estelle Rolland, et al.
The Lancet. Oncology|February 24, 2015
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialNaiyer A Rizvi, Julien Mazières, David Planchard, et al.
The European Respiratory Journal|September 29, 2018
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trialGuy Meyer, Benjamin Besse, Hélène Doubre, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 9, 2025
Human Immunodeficiency Virus Impairs Immune Responses to Tumor Neoepitopes Without Altering Mutational Profiles in NSCLCBaptiste Abbar, Karim Labreche, Jacques Cadranel, et al.
Pageof 20

Showing results (181-190 of 193) with videos related to

Sort By:
Pageof 20
European Journal of Cancer (Oxford, England : 1990)|February 21, 2023
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018Olivier Bylicki, Pascale Tomasini, Gervais Radj, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2015
Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II StudyBenjamin Besse, Sylvestre Le Moulec, Julien Mazières, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 18, 2012
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2)Jacques Cadranel, Audrey Mauguen, Michele Faller, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R StudyNicolas Girard, Jair Bar, Pilar Garrido, et al.
Current Oncology (Toronto, Ont.)|March 27, 2026
Real-World Treatment Patterns and Survival in Patients with <i>ROS1</i>-Positive Advanced Non-Small Cell Lung Cancer in Canada and EuropeWinson Y Cheung, Adam Lee, Helena Bote de Cabo, et al.
Advances in Therapy|January 18, 2023
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion MutationsChristos Chouaid, Lise Bosquet, Nicolas Girard, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2011
Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1)Michèle Beau-Faller, Armelle Degeorges, Estelle Rolland, et al.
The Lancet. Oncology|February 24, 2015
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialNaiyer A Rizvi, Julien Mazières, David Planchard, et al.
The European Respiratory Journal|September 29, 2018
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trialGuy Meyer, Benjamin Besse, Hélène Doubre, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 9, 2025
Human Immunodeficiency Virus Impairs Immune Responses to Tumor Neoepitopes Without Altering Mutational Profiles in NSCLCBaptiste Abbar, Karim Labreche, Jacques Cadranel, et al.
Pageof 20